Gyeonggi-do, South Korea

Mahnhoon Park

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Sk Chemicals Co., Ltd.. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mahnhoon Park. Retrieved from https://idiyas.com/inventor/mahnhoon-park-s066kmxw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mahnhoon Park: A Visionary in Biotechnology

Introduction

Mahnhoon Park is an innovative inventor based in Yongin-si, Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, although he currently holds no patents. His work has been influential in advancing the industry and improving health outcomes.

Latest Patents

As of now, Mahnhoon Park has not registered any patents. Despite this, his expertise and experience in biotechnology are noteworthy.

Career Highlights

Mahnhoon Park has worked with prominent companies such as SK Bioscience Co., Ltd. and SK Chemicals Co., Ltd. His roles in these organizations have allowed him to develop his skills and contribute to various projects that aim to enhance biotechnological applications.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Mahnhoon Park is a dedicated inventor whose work in biotechnology continues to inspire innovation. His career reflects a commitment to advancing the field, and his future contributions are anticipated with great interest.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…